COMPOSITIONS AND METHODS FOR INHIBITING TOXIN A FROM CLOSTRIDIUM DIFFICILE

• US 20090280134A1
• Filed: 05/11/2009
• Published: 11/12/2009
• Est. Priority Date: 05/09/2008
• Status: Abandoned Application

• Current Assignee: Recopharma AB
• Original Assignee: Recopharma AB
• Inventors: Gustafsson, Anki, Holgersson, Jan
• Application Number:
  US12/463,951
• Publication Number:
  US 20090280134A1
• Time in Patent Office: Days
• US Class Current: 424/183.100
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61K 38/1735 Mucins, e.g. human intestinal mucin
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention provides compositions and methods for treating or preventing infection by Toxin A producing bacteria.

Claims

1. A method for preventing or alleviating a symptom of bacterial toxin infection in a subject in need thereof, the method comprising administering to the subject fusion polypeptide comprising a first polypeptide linked to a second polypeptide, wherein the first polypeptide:

(a) is a mucin polypeptide; and

(b) is glycosylated by an α

1,3 galactosyltranserase and a β

1,6, N-acetylglucosaminyltransferase; and

the second polypeptide comprises at least a region of an immunoglobulin polypeptide.

3. The method of claim 1 or 2, wherein the bacterial toxin is produced by Clostridium difficile.

4. The method of claim 1 or 2, wherein the bacterial toxin is C. difficile Toxin A.

5. The method of claim 1 or 2, wherein the fusion polypeptide is administered systemically.

6. The method of claim 1 or 2, wherein the fusion polypeptide is administered rectally.

2. A method for preventing or alleviating a symptom of bacterial toxin infection in a subject in need thereof, the method comprising administering to the subject a fusion polypeptide comprising a first polypeptide linked to a second polypeptide, wherein

a) the fusion polypeptide comprises a glycan repertoire including one or more sequences, or a fragment thereof, selected from the group consisting of:

i) Hex-HexNol-HexN-Hex-Hex

ii) NeuAc-Hex-HexNol-HexN-Hex-Hex and

iii) NeuGc-Hex-HexNol-HexN-Hex-Hex; and

b) the second polypeptide comprises at least a region of an immunoglobulin polypeptide.